itolizumab   Click here for help

GtoPdb Ligand ID: 9421

Synonyms: Alzumab® | T1h
Approved drug Immunopharmacology Ligand
itolizumab is an approved drug (DCGI (India; 2013))
Compound class: Antibody
Comment: Itolizumab is a first in class humanized IgG1 monoclonal antibody targeting T cell CD6. It is being developed by Biocon Limited for its anti-inflammatory potential in autoimmune conditions.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
Itolizumab downregulates CD6-induced T-cell activation, inhibiting the synthesis of pro-inflammatory cytokines by T-helper (Th) 17 cells. However, the presence of CD6 on all T cells, and the lack of clarity around whether CD6 is a positive or negative co-stimulator of T-cell activation, warrants caution regarding the potentially widespread immunomodulatory effects of anti-CD6 therapy.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
 Approved drug for chronic plaque psoriasis.